In the current era, the impact of bone marrow plasma-cell percentage (BMPC%) at diagnosis of multiple myeloma (MM) is not well described. We evaluated the prognostic impact of BMPC% ≥ 60% versus < 60% in 1426 newly diagnosed MM patients. Median progression-free and overall survival were shorter for patients with BMPC% ≥ 60%, even in a multivariate analysis that included known prognostic factors for MM.
|Original language||English (US)|
|Number of pages||6|
|Journal||Clinical Lymphoma, Myeloma and Leukemia|
|State||Published - Sep 2020|
- Tumor burden
ASJC Scopus subject areas
- Cancer Research